Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?

Journal of Rheumatology

Volumn 26, Issue SUPPL. 56, 1999, Pages 31-36

  Geis, G Steven ^a,b  

^a PFIZER INC   (United States)

^b Clinical Research   (United States)

Author keywords

Analgesic drugs; Antiinflammatory drugs; Arthritis; Celecoxib; Cyclooxygenase; Gastrointestinal effects; Platelet effects

Indexed keywords

CELECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; BLOOD PLATELETS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0032962232     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. IMS retail and mail order audits, September 1996 - August 1997.
2. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18 Suppl 28:6-10.
3. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-8S.
4. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
5. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991;324:1716-25.
6. Hart D, Lifschitz MD. Renal physiology of prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 1987;7:408-18.
7. Vane JR, Botting RM. Biological products of cyclooxygenase products. In: Cunningham FM, editor. Lipid mediators. London, San Diego: Academic Press; 1994:61-97.
8. Rees WDW, Shorrock CJ. Overview of gastroduodenal mucosal protection. Am J Med 1988;2A:761-6.
9. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24:6-7.
10. Vane JR, Botting RM. Overview - mechanisms of actions of anti-inflammatory drugs. In: Vane J, Botting J, Botting R, editors. Improved non-steroidal anti-inflammatory drugs: COX-2 enzyme inhibitors. Boston: Kluwer Academic Publishers; 1996:1-27.
11. Simon LS. Nonsteroidal anti-inflammatory drugs and their effects: the importance of COX "selectivity." J Clin Rheumatol 1996; 2:135-40.
12. Pairet M, Churchill L, Engelhardt G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: Bozan N, Bolting J, Vane JR, editors. New targets in inflammation, inhibitors of COX-2 or adhesion molecules. Dordrecht, Netherlands: Kluwer Academic Publishers; 1996:23-38.
13. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzene sulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-65.
14. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995;305:479-84.
15. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998;41:1591-602.
16. Hubbard RC, Koepp R, Yu SS, Talwalker S, Geis GS. Pilot study of SC-58635, a COX-2-selective inhibitor, in rheumatoid arthritis [abstract]. Arthritis Rheum 1997;40 Suppl:S51.
17. Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor [abstract]. Arthritis Rheum 1997;40 Suppl:S93.
18. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cylcooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
19. Lanza FL, Callison DA, Hubbard RC, Yu SS, Talwalker S, Geis GS. A pilot study of the gastroduodenal effects of SC-58635, a COX-2-selective inhibitor [abstract]. Arthritis Rheum 1997;40 Suppl:S93.